Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 10/20 | 0.72 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908950 | 0.90 | S1PR2 (0.70) | S1PR2RHEBKMT2ALMNANPC1 | |
| SCHEMBL23908734 | 0.90 | S1PR2 (0.69) | S1PR2RHEBLMNANPC1MITF | |
| SCHEMBL23908842 | 0.89 | S1PR2 (0.79) | S1PR2KMT2AMEN1 | |
| SCHEMBL23966552 | 0.89 | S1PR2 (0.84) | S1PR2RHEBNPC1RAB9A | |
| SCHEMBL23914682 | 0.89 | S1PR2 (0.69) | S1PR2RHEBLMNATP53NPC1 | |
| SCHEMBL23908755 | 0.88 | S1PR2 (0.68) | S1PR2RHEBPIK3CDPIK3CBKMT2A | |
| SCHEMBL23908835 | 0.86 | S1PR2 (0.66) | S1PR2RHEBKMT2AHTTMEN1 | |
| SCHEMBL23966848 | 0.86 | S1PR2 (0.72) | S1PR2RHEBTP53 | |
| SCHEMBL23908735 | 0.86 | S1PR2 (0.66) | S1PR2RHEBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL23908779 | 0.86 | S1PR2 (0.65) | S1PR2RHEBPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885RHEB 2911/4885PIK3CD 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.